Metabolic Steatotic Liver Disease
Current Knowledge, Therapeutic Treatments, and Future Directions
- 1st Edition - June 21, 2024
- Imprint: Academic Press
- Editors: Mindie Nguyen, Linda Henry
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 9 6 4 9 - 5
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 9 6 5 0 - 1
Metabolic Fatty Liver Disease: Current Knowledge, Therapeutic Treatments, and Future Directions provides the most updated research findings and defines the current data gaps on m… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteMetabolic Fatty Liver Disease: Current Knowledge, Therapeutic Treatments, and Future Directions provides the most updated research findings and defines the current data gaps on metabolic fatty liver disease. The book extensively covers key areas in metabolic fatty liver disease research, including epidemiology (adults and children), economic burden, patient-reported outcome burden, natural history, current treatments, current diagnostic methods, controversies (NAFLD/MAFLD), current guidelines, fatty liver disease in the presence of other liver diseases as well as guidance on future research.
This book will provide translational researchers with a current and comprehensive resource dedicated to all aspects of research in metabolic fatty liver disease, identify current gaps in research and make future research recommendations. It also offers clinicians a look at important background information in metabolic fatty liver disease and thoroughly reviews the latest research in this area to inform treatment outcomes.
- Compiles the latest, up-to-date science from key experts in the field on metabolic fatty liver disease
- Reviews best practices and current guidelines for a comprehensive overview
- Identifies recommendations for future research endeavors
Translational and clinical science researchers in digestive medicine; gastroenterologists and hepatologists, Bariatric surgeons, transplant surgeons, nutritionists, endocrinologists, cardiologists, public and health policy makers
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter 1. Global epidemiology of NAFLD
- Epidemiology of NAFLD
- Projections for the burden of NAFLD
- Factors contributing to the increasing burden of NAFLD
- Conclusion
- Chapter 2. The epidemiology of non-alcoholic fatty liver disease in the United States
- Introduction
- Overall prevalence of NAFLD in the United States
- Prevalence of NAFLD by race/ethnicity
- Prevalence of NAFLD by age and gender
- Other epidemiology areas among those with NAFLD
- Forecasted prevalence
- Summary
- Chapter 3. Economic and patient reported outcome burden of NAFLD
- Introduction
- Economic burden of NAFLD
- Economic burden of NASH forecasted
- Patient reported outcomes and health related quality of life in NAFLD and NASH
- Work productivity
- Fatigue
- Societal impact
- Chapter 4. Pathogenesis of NAFLD/NASH
- Environmental factors
- Genetic and epigenetic factors in non-alcoholic fatty liver disease
- Epigenetic factors
- The gut microbiota in NAFLD
- Microbiome composition in NAFLD
- Microbiome function in NAFLD
- The future for microbiota in NAFLD
- Animal models in NASH
- Diet-induced models
- Genetically modified models
- Conclusions
- Chapter 5. Natural history of nonalcoholic fatty liver disease
- Introduction
- Challenges in determining natural history
- Onset of disease (steatosis)
- Progression to and from steatohepatitis (NASH)
- Development of fibrosis and cirrhosis
- Hepatic decompensation and liver-related mortality
- Hepatocellular carcinoma (NAFLD-HCC)
- Multimorbidity and extra-hepatic outcomes
- Conclusion
- Chapter 6. Clinical diagnosis and evaluation pathway
- Introduction
- Diagnosis of NAFLD
- MAFLD as a new definition of NAFLD
- Differentiating between alcohol-associated liver disease (ALD) and NAFLD
- Clinical phenotyping in NAFLD
- NAFLD screening
- Initial evaluation of NAFLD
- Fibrosis staging in NAFLD
- Role of liver biopsy in NAFLD
- Referral of patients for specialist evaluation
- Conclusion
- Chapter 7. Nonalcoholic fatty liver disease–related extrahepatic complications, associated outcomes, and their treatment considerations
- Introduction
- Cardiovascular/cerebrovascular disease
- Chronic kidney disease
- Sleep disorders: Obstructive sleep apnea
- Extrahepatic cancer
- Conclusions
- Chapter 8. Metabolic comorbidities, endocrine—Diabetes, polycystic ovarian syndrome, thyroid dysfunction
- Diabetes and nonalcoholic fatty liver disease
- Polycystic ovarian syndrome and NAFLD
- Thyroid dysfunction and NAFLD
- NAFLD and other endocrine conditions
- Summary
- Chapter 9. Noninvasive, serum-based evaluation of liver fibrosis in metabolic (dysfunction)-associated fatty liver disease
- Introduction
- Prognostic significance of liver fibrosis
- Serum-based biomarkers of liver fibrosis
- Conclusions
- Chapter 10. Noninvasive evaluation of liver fibrosis in MASLD—Imaging/elastography based
- Introduction
- Routine imaging techniques
- Ultrasound elastography
- Other MRI techniques
- Factors confounding liver stiffness measurements
- Chapter 11. Clinical management of MASLD and MASH—An overview
- Introduction
- Diagnosis and risk stratification
- Stage-dependent treatment of MASLD/MASH
- Conclusions and outlook
- Chapter 12. Nonpharmacologic and nonsurgical treatment of NAFLD/NASH, obesity, and metabolic disease
- Introduction
- Weight reduction as a desired endpoint
- The role of physical activity on NAFLD and MetS
- The effect of diet on NAFLD and MetS
- Conclusion
- Chapter 13. Pharmacologic treatment of NAFLD/NASH and their related comorbidities
- Trial endpoints for evaluation of NASH therapies
- Nuclear receptor targets
- Fibroblast growth factor analogs
- SCD-1 inhibitor
- Fatty acid synthase inhibitors
- Endogenous metabolic modulators
- Anti-inflammatory agents
- Monoclonal antibody therapies for NASH
- Antifibrotic therapies in cirrhosis
- Combination therapies
- Using currently approved therapies for treatment of those with NAFLD and NASH
- Management of diabetes, dyslipidemia, and obesity in those with NASH
- Summary
- Disclosures
- Chapter 14. Surgical treatment of obesity for NAFLD
- When to consider the surgical option?
- Patient selection
- Types of surgical options
- Endoscopic bariatric procedures
- Long-term outcomes
- Conclusion
- Chapter 15. Metabolic dysfunction-associated steatotic liver disease in children and adolescents
- Introduction
- Epidemiology
- Natural history and progression
- Screening for fatty liver and fibrosis
- Diagnosis
- Liver biopsy and histology
- Treatment
- Surgical options
- Long-term care for children with MASLD
- Conclusions
- Chapter 16. Fatty liver and viral hepatitis: Prevalence, risk factors, natural course, pathogenesis, and management
- Introduction
- CHB and FLD
- The natural course of combined CHB and FLD
- Managements of combined CHB and FLD
- CHC and FLD
- The link between steatosis and CHC and the risk factors
- The pathogenesis of steatosis in HCV: Metabolic steatosis versus viral steatosis
- The mutual impact between steatosis and sustained virological response
- Summary
- Chapter 17. Lean NAFLD: Prevalence, risk factors/pathogenesis, natural history, and treatment
- Definition and prevalence of lean NAFLD
- Risk factors and pathogenesis of lean or nonobese NAFLD
- Gut microbiome
- Other risk factors
- Natural history and prognosis of lean/nonobese NAFLD
- Prognosis of lean/nonobese NAFLD
- Treatment for lean/nonobese NAFLD
- Chapter 18. Future directions for fatty liver disease
- The controversy over terminology: Is it legitimate?
- Prevention
- Increasing awareness
- Long-term outcomes from treatment
- Index
- Edition: 1
- Published: June 21, 2024
- Imprint: Academic Press
- No. of pages: 338
- Language: English
- Paperback ISBN: 9780323996495
- eBook ISBN: 9780323996501
MN
Mindie Nguyen
Dr. Nguyen is Professor of Medicine and Director for the Hepatology Fellowship in the Division of Gastroenterology and Hepatology and Liver Transplant Program and by courtesy Professor of Epidemiology and Population Health at Stanford University Medical Center and Director for the Hepatology Clerkship for Stanford University School of Medicine. She is also a member of the Stanford Cancer Institute, Stanford Bio-X and Stanford Population Science. She has served as a member of the Appointment and Promotion Committee for the Department of Medicine as well as a Diversity LENS Advocate for the Department. She is both clinically active and does research with single-center Stanford-based cohorts, multi-center Bay Area consortium, multi-center US consortia as well as international cohorts. She is a Fellow of the American Association for the Study of Liver Diseases and the American Gastroenterological Association, as well as member of the American College of Gastroenterology, European Association for the Study of Liver Diseases and the Asia Pacific Association for the Study of Liver Diseases.
Affiliations and expertise
Professor of Medicine and Director, Hepatology Fellowship, Division of Gastroenterology and Hepatology and Liver Transplant Program; Courtesy Professor of Epidemiology and Population Health, Stanford University Medical Center; Director, Hepatology Clerkship for Stanford University School of MedicineLH
Linda Henry
Linda Henry is an academic researcher from Stanford University. The author has contributed to research in topic(s): Hepatitis C & Sofosbuvir. The author has an hindex of 42, co-authored 197 publication(s) receiving 12359 citation(s). Previous affiliations of Linda Henry include Inova Health System & University of Florida.
Affiliations and expertise
Academic Researcher, Stanford University, USARead Metabolic Steatotic Liver Disease on ScienceDirect